FIBROGEN INC
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
KYNB$3.73+1.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Financial Statements and Supplementary Data
| Page | |
|---|---|
| FibroGen, Inc. | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | 95 |
| Financial Statements: | |
| Consolidated Balance Sheets | 97 |
| Consolidated Statements of Operations | 98 |
| Consolidated Statements of Comprehensive Loss | 99 |
| Consolidated Statements of Changes in Stockholders’ Equity (Deficit) | 100 |
| Consolidated Statements of Cash Flows | 101 |
| Notes to Consolidated Financial Statements | 102 |
| Financial Statement Schedule: | |
| II Valuation and Qualifying Accounts for each of the three years ended December 31, 2023 | 150 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.